2021
Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria
Hoppe BS, Advani R, Milgrom SA, Bakst RL, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Mansur DB, Metzger ML, Pinnix CC, Plastaras JP, Roberts KB, Smith SM, Terezakis SA, Kirwan JM, Constine LS. Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 36-44. PMID: 33774076, DOI: 10.1016/j.ijrobp.2021.03.035.Peer-Reviewed Original ResearchMeSH KeywordsHumansLymphoma, B-CellMediastinal NeoplasmsPositron Emission Tomography Computed TomographyRadiotherapy Planning, Computer-AssistedConceptsPrimary mediastinal B-cell lymphomaMediastinal B-cell lymphomaB-cell lymphomaPET/CT responsePositron emission tomographyCell lymphomaDeauville scaleRadiation therapyCT responseAmerican Radium Society Appropriate Use CriteriaLong-term treatment-related morbiditySystematic reviewTreatment-related morbidityConsolidative radiation therapyAppropriate use criteriaEvidence-based guidelinesNon-Hodgkin lymphomaMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsChemoimmunotherapy strategiesCurable subtypeAdditional therapyChemoimmunotherapy regimensRefractory diseasePediatric oncologists
2015
ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma
Dabaja BS, Advani R, Hodgson DC, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. American Journal Of Clinical Oncology 2015, 38: 610-620. PMID: 26583344, DOI: 10.1097/coc.0000000000000215.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaAppropriateness CriteriaRole of radiationPositron emission tomography/Ann Arbor stagingAppropriateness of imagingDifferent chemotherapy regimensACR Appropriateness CriteriaRecent prospective studiesInternational Prognostic IndexRadiology Appropriateness CriteriaMultidisciplinary expert panelEvidence-based guidelinesEmission tomography/Specific clinical conditionsCurrent medical literatureChemotherapy regimensPeer-reviewed journalsInitial diagnosisPrognostic indexProspective studyRetrospective studyTomography/
2000
Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Rizzieri D, Vermont C, Clough R, Kim C, Dodge R, Prosnitz L. Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1097-1105. PMID: 11072168, DOI: 10.1016/s0360-3016(00)00695-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisoneProcarbazineRadiotherapy DosageRetrospective StudiesTreatment FailureVinblastineVincristineConceptsLarge mediastinal adenopathyHodgkin's disease patientsComplete responseDisease patientsInduction chemotherapyInduction failureGallium scanMediastinal adenopathyModality therapyRT doseComplete clinical stagingLow-dose radiotherapyResidual radiographic abnormalitiesCycles of chemotherapyFailure-free survivalPhase III trialsPatterns of failureConsolidation radiationChemotherapy regimensCR patientsIII trialsOverall survivalClinical stagingHD patientsRadiographic abnormalities